MBM ScienceBridge GmbH negotiates license agreement between the Georg-August University of Göttingen and Nordgetreide GmbH & Co. KG
Modern packaging must do much more than simply meet the specific requirements for transport, storage and presentation: it must also be sustainable. But what does sustainable really mean? It means that the material must be environmentally friendly and made from renewable resources, be sturdy enough to enable re-use and be easy to recycle when it comes to the end of its useful life. For many years, a research group at the University of Göttingen has put their energy and expertise into investigating manufacturing processes for products made of popcorn. These products have the potential to be environmentally friendly alternatives to polystyrene or plastic. The University has now signed a licence agreement with the company Nordgetreide for the commercial use of the process and products for the packaging sector.
Scientists at the University of Göttingen develop drug for antibody tumour therapy
Chemists at the University of Göttingen have developed new cytotoxic drugs which could revolutionise antibody-based tumour therapy approaches. The research team succeeded in modifying the natural product Duocarmycin into “prodrug” formats – which means that it only develops its effect once inside the tumour cell, thus reducing the likelihood of potential side effects on passage through the body. The University has entered into an exclusive licence agreement with the biotechnology company Iksuda Therapeutics for onward development and commercialisation in cancer therapeutics.
Antibody tumour therapies have enabled significant therapeutic benefits to patients suffering from cancer, autoimmune diseases and other serious diseases. However, many antibodies lack sufficient anti-tumour activity in the cell. This can be achieved by the use of antibody-drug conjugates (ADCs), where antibodies, which target specific cancer antigens, are armed with powerful cell-killing (cytotoxic) agents or ‘payloads’. ADCs have become powerful additions to the cancer treatment armoury, with several recent drug approvals and expanding clinical validation. However, most early-wave ADCs are associated with poor tolerability profiles, often due to a reduction in efficacy caused by the loss of the toxic payload whilst in circulation. Some programmes have failed as a result of low efficacy, where the payload is not active enough once inside the cell. ADC innovators, such as Iksuda, are working on the development of ADCs with a higher therapeutic index and finding safer ways to deliver potent cell-killing toxins. Iksuda has developed their own stable conjugation platform which reduces the risk of loss of efficacy.
One way to enhance both safety and efficacy of an ADC is to ensure that the payload is only released via tumour-activated mechanisms. With this approach, the precursors, called prodrugs, are able to release more potent payloads inside the cancer cell, with limited impact outside the cell.
MBM ScienceBridge GmbH has successfully negotiated an extension of the existing license agreement between the Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin (UMG) and the Göttingen-based biotech company Tissue Systems Holding GmbH on the extended commercial use of culturing methods for standardized production of human micro tissues and stem cell-based cells. The technologies are based on the scientific achievements in the field of stem cell based tissue engineering and laboratory automation of the research team led by Prof. Dr. Wolfram-Hubertus Zimmermann, Director of the Institute of Pharmacology and Toxicology at the University Medical Center of Göttingen. The extended exclusive license agreement provides for one-time payments and, in addition to sales-related license fees, an annual minimum license fee.
Nowadays, search for suitable drug candidates and risk assessments are mainly carried out using cell cultures and animal models. However, these models have limited significance for the human organism. The lack of organ physiologiology and functional maturity in standard cell cultures is a challenge that needs to be overcome. "The key to drug development are models based on tissue engineering with functional properties that are characteristic for health and disease. The platforms developed at UMG are aimed at the highest degree of functional maturation. They enable detailed impact analyses and a rational dosage strategy for early clinical studies", says Prof. Zimmermann.